SCHEMBL9890778

SCHEMBL9890778

Cc1ccc(-c2ccc(Cl)cc2)c(CC(N)=O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.48
CYP2C19 P33261 1/20 0.45
ICMT O60725 4/20 0.44
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KMT2A Q03164 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43
FFAR1 O14842 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
PRKCZ Q05513 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ANO1 Q5XXA6 1/20 0.39
DHODH Q02127 2/20 0.39
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395091 0.87 CYP2C19 (0.49) CYP2C19ICMTALDH1A1FFAR1FFAR4
SCHEMBL9890673 0.86 PTGDR2 (0.52) GRM2KDM4EMEN1ALDH1A1KMT2A
SCHEMBL9890761 0.84 PTGDR2 (0.47) ICMTKDM4EALDH1A1KMT2APTGDR2
SCHEMBL9890779 0.82 ALDH1A1 (0.44) GRM2CYP2C19KDM4EMEN1ALDH1A1
SCHEMBL9890772 0.82 CYP2C19 (0.45) CYP2C19ICMTANO1DHODH
SCHEMBL9890770 0.79 ICMT (0.43) CYP2C19ICMTKDM4ESIRT1NPC1
SCHEMBL9892683 0.78 PTGDR2 (0.51) CYP2C19ICMTPTGDR2ANO1DHODH
SCHEMBL9890727 0.78 FFAR1 (0.49) CYP2C19ALDH1A1KMT2APTGDR2FFAR1
SCHEMBL6184923 0.78 CYP2C19 (0.64) CYP2C19KDM4EALDH1A1KMT2APTGDR2
SCHEMBL3741692 0.77 FFAR1 (0.57) KDM4EMEN1ALDH1A1KMT2APTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 GRM2 504/4885CYP2C19 240/4885ICMT 2894/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 GRM2 504/4885CYP2C19 240/4885ICMT 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.